Teoxane

Teoxane is a global specialist in hyaluronic acid science, founded in 2003 by Valérie Taupin and headquartered in Geneva, Switzerland, where it carries out integrated research, development and manufacturing. The company develops injectable dermal fillers and professional dermocosmetics, and sells its products in more than 90 countries through a network of subsidiaries and distributors, with some 40 million syringes sold worldwide by 2025.

Its product portfolio includes the TEOSYAL injectable filler range, designed to adapt to natural facial movement, and the RHA (Resilient Hyaluronic Acid) range. Several RHA products have received FDA approval; RHA 4 with Mepivacaine was approved in 2025 for midface augmentation. Teoxane also produces professional skincare formulated for hydration, skin quality and post-procedure care, alongside educational programmes and clinical techniques for healthcare practitioners, including the ATP approach and the Multi Layering Technique.

Technical work spans hyaluronic acid science, injectable filler development, dermocosmetics formulation, clinical research, aesthetic medicine techniques and regulatory affairs. The company's R&D organisation holds more than 180 patent titles, and it has supported 23 clinical studies involving over 800 patients. Industry verticals include medical aesthetics, injectable pharmaceuticals, dermocosmetics and practitioner training.

Teoxane maintains in-house research, development and manufacturing in Geneva and places emphasis on scientific rigour and on education and training for healthcare professionals.